MDxHealth Targets LDTs, US Market as Part of Makeover | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – In late 2006, Johnson & Johnson unit Veridex entered into a licensing deal with OncoMethylome Sciences for a prostate cancer test. The deal, the Belgian cancer research firm thought, would result in a steady stream of product revenues for years to come.

At the time, OncoMethylome had finished the initial research phase for the three-marker urine-based test, and Veridex planned to finish the research. If all went well, Veridex would commercialize the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.